

ELITE PHARMACEUTICALS INC /DE/  
Form 8-K  
October 01, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

September 29, 2008

-----  
Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS, INC.  
-----

(Exact name of registrant as specified in its charter)

Delaware  
-----

(State or other jurisdiction  
of incorporation)

001-15697  
-----

(Commission  
File Number)

22-3542636  
-----

(IRS Employer  
Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647  
-----

(Address of principal executive offices)

(201) 750-2646  
-----

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  
(17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events**

On September 29, 2008 the Registrant issued a press release announcing the acceptance by the U.S. Food and Drug Administration (the "FDA") of the Abbreviated New Drug Application for a generic equivalent of a synthetic narcotic analgesic drug product that was filed with the FDA in collaboration with ThePharmaNetwork, LLC.

A copy of the Press Release, dated September 29, 2008, is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

- a) Not applicable.
- b) Not applicable.
- c) Not applicable.
- d) Exhibits

Exhibit No.	Exhibit
99.1	Press Release, dated September 29, 2008

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 1, 2008

ELITE PHARMACEUTICALS, INC.

By: /s/ Bernard Berk  
Name: Bernard Berk  
Title: Chief Executive Officer